FDA Agreement on Mesoblast's Use of Singapore Manufacturing Facility for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells
February 12, 2013 20:28 ET
|
Mesoblast
MELBOURNE, Australia, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY) today announced that United States Food and Drug Administration (FDA) is in agreement for Mesoblast...
Key Mesenchymal Precursor Cell Patents Granted in United States and China
February 06, 2013 19:40 ET
|
Mesoblast
MELBOURNE, Australia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been granted three key new patents by the...
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis
January 29, 2013 20:25 ET
|
Mesoblast
Key Points:
Mesoblast receives clearance from United States Food and Drug Administration (FDA) to begin Phase 2 trial of proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells...
Mesoblast's NeoFuse Stem Cell Product Shows Positive Results in Phase 2 Lumbar Spinal Fusion Trial
January 10, 2013 22:35 ET
|
Mesoblast
Key points:
Phase 2 trial results using Mesoblast's allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) demonstrated rates of fusion success that were comparable to the gold...